Catawba Capital Management’s Gilead Sciences GILD Stock Holding History

Catawba Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$220K	Buy	+3,110	New	+$220K	0.05%	196

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Catawba Capital Management's GILD Position: Q2 2018 in Review

Catawba Capital Management opened a new position in Gilead Sciences (GILD) in Q2 2018: 3,110 shares worth $220K. The stake represents 0.05% of the portfolio and ranks #196 among its holdings.

1,523 funds tracked by Wall St. Rank hold GILD as of Q2 2018.

Catawba Capital Management held 3,110 shares of Gilead Sciences worth $220K as of Q2 2018.
Gilead Sciences was a new Catawba Capital Management position in Q2 2018.
Gilead Sciences made up 0.05% of Catawba Capital Management's portfolio in Q2 2018, its #196 holding.
1,523 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.